BMY Shares Outstanding History
Below is a table of the BMY shares outstanding history going back to 2/1/2010:

Date BMY Shares Outstanding
2/1/20101.71B
3/31/20101.72B
6/30/20101.71B
9/30/20101.71B
2/1/20111.70B
3/31/20111.71B
6/30/20111.71B
9/30/20111.69B
2/1/20121.69B
3/31/20121.69B
6/30/20121.68B
9/30/20121.65B
2/1/20131.64B
3/31/20131.64B
6/30/20131.65B
9/30/20131.65B
2/1/20141.65B
3/31/20141.66B
6/30/20141.66B
9/30/20141.66B
2/2/20151.66B
3/31/20151.67B
6/30/20151.67B
9/30/20151.67B
2/1/20161.67B
3/31/20161.67B
6/30/20161.67B
9/30/20161.67B
2/1/20171.67B
3/31/20171.65B
6/30/20171.64B
9/30/20171.64B
2/1/20181.63B
3/31/20181.63B
6/30/20181.63B
9/30/20181.63B
2/1/20191.63B
3/31/20191.64B
6/30/20191.64B
9/30/20191.63B
2/3/20202.26B
3/31/20202.26B
6/30/20202.25B
9/30/20202.26B
2/1/20212.24B
3/31/20212.23B
6/30/20212.22B
9/30/20212.22B
2/1/20222.18B
3/31/20222.13B

Also see: BMY Market Cap History
BMY YTD Return
BMY RSI
BMY DMA
BMY MACD
BMY Technical Analysis
BMY Historical Shares Outstanding:
+1.80% CAGR
BMY Historical Shares Outstanding: +1.80% CAGR

Mouse over chart for data details
2/1/2010 ...3/31/2022
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy. We show 50 historical shares outstanding datapoints in our coverage of BMY's shares outstanding history.

Understanding the changing numbers of BMY shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like BMY versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching BMY by allowing them to research BMY shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree BMY Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Bristol-Myers Squibb (BMY) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

BNGO Shares Outstanding History
BNTC Shares Outstanding History
BOLD Shares Outstanding History
BOLT Shares Outstanding History
BPMC Shares Outstanding History
BPTH Shares Outstanding History
BRKR Shares Outstanding History
BRLI Shares Outstanding History
BRTX Shares Outstanding History
BSGM Shares Outstanding History
More Healthcare companies »

 

BMY Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2022, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.